TNA
AQST icon

True North Advisors’s Aquestive Therapeutics AQST Stock Holding History

True North Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-32,295
Closed -$70K – 190
2020
Q1 		$70K Hold
32,295
– – 0.02% 119
2019
Q4 		$187K Buy
+32,295
New +$168K 0.05% 112

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

True North Advisors's AQST Position: Q2 2020 in Review

True North Advisors sold out of Aquestive Therapeutics (AQST) in Q2 2020, closing a stake of 32,295 shares — an estimated $70K sold.

True North Advisors first reported a position in AQST in Q4 2019 and held it in 2 quarters. The position peaked at $187K in Q4 2019. 57 funds tracked by Wall St. Rank hold AQST as of Q2 2020.

  • True North Advisors reported no remaining Aquestive Therapeutics position as of Q2 2020 after selling out during the quarter.
  • True North Advisors sold 32,295 Aquestive Therapeutics shares in Q2 2020, an estimated $70K.
  • True North Advisors first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 2 quarters.
  • True North Advisors's Aquestive Therapeutics position peaked at $187K in Q4 2019.
  • 57 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2020.

Based on True North Advisors's 13F filing for Q2 2020, filed 20 May 2022.